Resources from the same session
2162 - Clinical Benefit and Prices of Cancer Drugs in the US and Europe
Presenter: Kerstin Vokinger
Session: Poster Discussion - Public policy
Resources:
Abstract
4743 - Determinants of the Cancer Drug Funding Process in Canada
Presenter: Joanna Gotfrit
Session: Poster Discussion - Public policy
Resources:
Abstract
6081 - Biosimilar Substitution: European Prescriber Perspectives
Presenter: Michael Reilly
Session: Poster Discussion - Public policy
Resources:
Abstract
1218 - Cost avoided in drugs derived from participation in clinical trials in colorectal cancer
Presenter: Luis Sánchez- Rubio Ferrández
Session: Poster Discussion - Public policy
Resources:
Abstract
3453 - Accessibility and Affordability to Trastuzumab for Breast cancer patients: voices of the Global Oncology community from ONCOLLEGE 001 survey – part 2
Presenter: Sara Altuna
Session: Poster Discussion - Public policy
Resources:
Abstract
3302 - Poster Discussion - Public policy - Analysis of 105.000 cancer patients; have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands
Presenter: Janneke Walraven
Session: Poster Discussion - Public policy
Resources:
Abstract
5246 - Reaching sustainable oncology care via the National Cancer Control Program (NCCP)
Presenter: Branko Zakotnik
Session: Poster Discussion - Public policy
Resources:
Abstract
5586 - Changing landscape of clinical cancer trials in Germany
Presenter: Susen Burock
Session: Poster Discussion - Public policy
Resources:
Abstract
5192 - Comparison between phase III randomized clinical trials and their preceeding phase II studies.
Presenter: Ivan Lyra-Gonzalez
Session: Poster Discussion - Public policy
Resources:
Abstract
5811 - Projecting overall survival data for health-economic models in oncology: do maturity levels impact uncertainty?
Presenter: Isabelle Borget
Session: Poster Discussion - Public policy
Resources:
Abstract